Global Membranous Nephropathy Market, By Treatment (Conservative Therapy, Non-Immunosuppressive Therapy, Immunosuppressive Therapy, Others), Drug Class (Alkylating Agents, Cyclophosphamide, Chlorambucil, Cyclic Peptides, Tacrolimus, MycophenolateMofetil, Others), Type (Primary, Secondary), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Membranous Nephropathy Market Analysis and Size
The global membranous nephropathy market is projected to grow at an extensive rate because of the increasing number of global kidney disorders and vulnerable elderly population. The impact of COVID-19 on membranous nephropathy market has started to be felt. The breakout of this disease led to lockdowns worldwide that has slowed down the growth of many markets. Membranous nephropathy market is no different. Though, the market is expected to catch up and grow rapidly in the forecast years.
Data Bridge Market Research analyses a growth rate in the global membranous nephropathy market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Membranous Nephropathy Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2014 - 2019) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Treatment (Conservative Therapy, Non-Immunosuppressive Therapy, Immunosuppressive Therapy, Others), Drug Class (Alkylating Agents, Cyclophosphamide, Chlorambucil, Cyclic Peptides, Tacrolimus, MycophenolateMofetil, Others), Type (Primary, Secondary), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.), FibroGen, Inc. (U.S.), Mayne Pharma Group Limited (Australia) |
|
Market Opportunities |
|
Market Definition
Membranous nephropathy is also known as silent kidney problem and is considered as a form of glomerular disease. It is occurred when the glomeruli became damage and thickened that causes edema and heavy proteinuria. As a result, it leads to reduced kidney function and swelling. Membranous nephropathy can be caused by numerous factors such as autoimmune disease, use of certain medications such as nonsteroidal anti-inflammatory drugs, and exposure to certain infections such as hepatitis B, hepatitis C, and syphilis.
Global Membranous Nephropathy Market Dynamics
Drivers
- Rising Population and Hepatitis Cases
According to the reports of United Nations, in 2017 around over 962 million population were aged over 60 and above worldwide. United Nations has also projected that by 2050, the older population will likely reach 425 million. Moreover, according to WHO, around 71 million people are affected with hepatitis C globally. This increasing aging population and increasing hepatitis cases are likely to boost the growth of the membranous nephropathy market.
- Increased Clinical Studies and Government Initiatives
The global diabetic nephropathy market is estimated to be driven by the rising R&D investments in drug discovery and development and the rising prevalence of diabetes. For instance, Novartis AG has a potential drug LNP023 which is in phase 2 of clinical trials. This is expected to boost the market growth.
Opportunities
- Increasing Demand for Retail Pharmacies
Rise in the number of open angle glaucoma therapeutics being delivered through retail pharmacies and increase in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients choose retail pharmacies for purchasing drugs, as these are easily accessible.
- Rising Demand for Diagnostic Tests
The different diagnostic tests are expected to create opportunities for the market growth. Tests such as urine test (urinalysis), glomerular filtration rate test, blood test, an antinuclear antibody test, kidney biopsy, an anti-PLA2R antibody test, kidney ultrasound or Computed Tomography (CT), and others.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global membranous nephropathy market over a forecast period.
- High Cost
The huge expenditure of the treatment and diagnostic methods hamper the market growth. Treatment includes different types of therapy such as conservative therapy, non-Immunosuppressive therapy, immunosuppressive therapy that are impeding the growth of the market.
This global membranous nephropathy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global membranous nephropathy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Membranous Nephropathy Market Scope
The global membranous nephropathy market is segmented on the basis of treatment, drug class, type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Conservative Therapy
- Non-Immunosuppressive Therapy
- Immunosuppressive Therapy
- Others
Drug Class
- Alkylating Agents
- Cyclophosphamide
- Chlorambucil, Cyclic Peptides
- Tacrolimus
- MycophenolateMofetil
- Others
Type
- Primary
- Secondary
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Membranous Nephropathy Market Regional Analysis/Insights
The global membranous nephropathy market is analyzed and market size insights and trends are provided by treatment, drug class, type, distribution channel and end-user as referenced above.
The major countries covered in the global membranous nephropathy market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the growing cases of hepatitis infections, the presence of sophisticated medical facilities to maximize the treatment effectiveness for patient and increases focuses in the research and development activity.
Asia-Pacific dominates the market due to the high diagnostic rate and presence of key players in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Membranous Nephropathy Market Share Analysis
The global membranous nephropathy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global membranous nephropathy market.
Key players operating in the global diabetic nephropathy market include:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hebei Changshan Biochemical Pharmaceutical Co. Ltd. (China)
- Hikma Pharmaceuticals PLC (U.K.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Bristol Myers Squibb Company (U.S.)
- FibroGen, Inc. (U.S.)
- Mayne Pharma Group Limited (Australia)
SKU-
